Una comparación aleatoria de la atención personalizada basada en la estadificación de la enfermedad cardíaca versus la atención habitual para la prevención de eventos (TRANSFORM)
Una comparación aleatoria de la atención personalizada basada en la estadificación de la enfermedad de las arterias coronarias versus la atención habitual para la prevención primaria de eventos cardiovasculares
TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Cardiovascular disease (CVD) persists as the leading cause of morbidity and mortality worldwide at high societal cost. The current primary CVD prevention strategy relies upon risk stratification using population health markers such as age, sex, diabetes, hypertension, dyslipidemia and tobacco use, with preventive therapy intensified in higher risk strata. Since these risk factors are indirect surrogate markers of the underlying disease, atherosclerosis, this strategy leads to treatment of individuals with risk factors who do not have atherosclerosis and failure to treat those with significant atherosclerosis who lack risk factors. The current strategy also cannot determine which individuals are inadequately treated despite effective risk factor management (residual risk). With the current approach, the CV death rate is trending upward in the US despite evidence that screening asymptomatic patients reduces CV events and the widespread availability of effective preventive therapies.
This randomized, controlled, pragmatic trial is designed to address the unmet need for better strategies to identify asymptomatic individuals at increased risk for CV events due to atherosclerosis and to personalize their treatment based on CV risk estimates using coronary artery disease (CAD) visualization and quantification.
This study enrolls patients without known symptoms of ASCVD but who are at increased risk for ASCVD due to their age and having diabetes, prediabetes or metabolic syndrome and tests the hypothesis that a CAD Staging System-based care strategy reduces CV events compared with risk factor-based care. The Cleerly CAD Staging System incorporates imaging-based evaluation for coronary atherosclerosis, algorithm-supported pharmacotherapy and personalized education about their CAD.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Ryann Sardinia
- Número de teléfono: 7207398191
- Correo electrónico: ryann.sardinia@cleerlyhealth.com
Copia de seguridad de contactos de estudio
- Nombre: Ashley Dunham, PhD
- Número de teléfono: 7207398191
- Correo electrónico: ashley.dunham@cleerlyhealth.com
Ubicaciones de estudio
-
-
Arizona
-
Chandler, Arizona, Estados Unidos, 85224
- Reclutamiento
- Chandler Clinical Trials
-
Contacto:
- Muhammad Salim, MD
-
Scottsdale, Arizona, Estados Unidos, 85260
- Reclutamiento
- Scottsdale Clinical Trials
-
Contacto:
- Todd Dreitzler, MD
-
Sun City, Arizona, Estados Unidos, 85381
- Reclutamiento
- Sun City Research
-
Contacto:
- Juan Rodriguez, MD
-
Tucson, Arizona, Estados Unidos, 85704
- Reclutamiento
- Noble Clinical Research
-
Contacto:
- Roxana Rodriguez, MD
-
-
California
-
Beverly Hills, California, Estados Unidos, 90210
- Reclutamiento
- Cardiovascular Research Foundation of Southern California
-
Contacto:
- Ronald P. Karlsberg, MD
-
Beverly Hills, California, Estados Unidos, 90211
- Reclutamiento
- Amicis Research: Beverly Hills
-
Contacto:
- Michael Levine, MD
-
Canoga Park, California, Estados Unidos, 91303
- Reclutamiento
- Valiance Clinical Research - Canoga Park
-
Contacto:
- Rami Shaarawy
-
Chula Vista, California, Estados Unidos, 91911
- Reclutamiento
- Cardiovascular Institute of San Diego
-
Contacto:
- Milind D. Parikh, MD
-
Granada Hills, California, Estados Unidos, 91324
- Reclutamiento
- Amicis Research: Granada Hills
-
Contacto:
- Pascal Dabel, MD
-
Huntington Park, California, Estados Unidos, 90255
- Reclutamiento
- Valiance Clinical Research: Huntington Park
-
Contacto:
- Philip Kim, MD
-
Indian Wells, California, Estados Unidos, 92210
- Reclutamiento
- HALO Diagnostics
-
Contacto:
- John F. Feller, MD
-
La Jolla, California, Estados Unidos, 92037
- Reclutamiento
- Scripps Health
-
Contacto:
- Elizabeth Epstein, MD
-
Lancaster, California, Estados Unidos, 93534
- Reclutamiento
- Chemidox Clinical Trials
-
Contacto:
- Pamela Dewar-DeSilva, MD
-
Loma Linda, California, Estados Unidos, 92354
- Reclutamiento
- Loma Linda University Health
-
Contacto:
- Purvi Parwani, MD
-
Long Beach, California, Estados Unidos, 90805
- Reclutamiento
- Long Beach Research Institute
-
Contacto:
- Ashley Duzik, MD
-
Monterey Park, California, Estados Unidos, 91754
- Reclutamiento
- Ace Research Institute - Monterey Park
-
Contacto:
- Yu-Hsiang Sam Lee, MD
-
Newhall, California, Estados Unidos, 91321
- Reclutamiento
- Amicis Research: Newhall
-
Contacto:
- Thuong Vo, MD
-
Northridge, California, Estados Unidos, 91324
- Reclutamiento
- Ace Research Institute: Northridge
-
Contacto:
- Richard Park, MD
-
Northridge, California, Estados Unidos, 91324
- Reclutamiento
- Amicis Research: Northridge
-
Contacto:
- Nana Barseghian, MD
-
Northridge, California, Estados Unidos, 91325
- Reclutamiento
- Ace Research Institute: Northridge #2
-
Contacto:
- William Y. Josephson, MD
-
Northridge, California, Estados Unidos, 91325
- Activo, no reclutando
- Northridge Clinical Trials
-
Orange, California, Estados Unidos, 92868
- Reclutamiento
- University of California- Irvine
-
Contacto:
- Ailin Barseghian El-Farra, MD
-
Palo Alto, California, Estados Unidos, 94304
- Reclutamiento
- Stanford Health Care
-
Contacto:
- Sandra Tsai, MD
-
Palo Alto, California, Estados Unidos, 94304
- Reclutamiento
- VA Palo Alto
-
Contacto:
- Shriram Nallamshetty, MD
-
San Fernando, California, Estados Unidos, 91306
- Reclutamiento
- Amicis Research: San Fernando
-
Contacto:
- Farid Yasharpour, MD
-
Tarzana, California, Estados Unidos, 91356
- Reclutamiento
- Valiance Clinical Research - Tarzana
-
Contacto:
- Harpreet Singh, MD
-
Torrance, California, Estados Unidos, 90502
- Reclutamiento
- Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center
-
Contacto:
- Suvasini Lakshmanan, MD
-
Valencia, California, Estados Unidos, 91355
- Reclutamiento
- Amicis Research: Valencia
-
Contacto:
- Dennis Lewis, MD
-
Valley Village, California, Estados Unidos, 91607
- Reclutamiento
- Concierge Clinical Trials
-
Contacto:
- Neal R. Cutler, MD
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Reclutamiento
- University of Colorado
-
Contacto:
- Steve Simon
-
Investigador principal:
- Steve Simon, MD
-
Denver, Colorado, Estados Unidos, 80218
- Reclutamiento
- St. Josephs (Intermountain Healthcare)
-
Contacto:
- Christopher Angus, MD
-
-
Florida
-
Boca Raton, Florida, Estados Unidos, 33434
- Reclutamiento
- Flourish Medical Research
-
Contacto:
- Michael Hafran, MD
-
Cross City, Florida, Estados Unidos, 32628
- Reclutamiento
- Apex Research
-
Contacto:
- Tamir Salmani, MD
-
Hialeah, Florida, Estados Unidos, 33012
- Reclutamiento
- Evolution Research Center
-
Contacto:
- Riquel Gonzalez, MD
-
Jacksonville, Florida, Estados Unidos, 32209
- Reclutamiento
- UF Health Jacksonville
-
Contacto:
- Luis Ortega Paz, MD
-
Miami, Florida, Estados Unidos, 33137
- Reclutamiento
- BioPhase Research
-
Contacto:
- Julie Cadet-Plassman, MD
-
Miami, Florida, Estados Unidos, 33135
- Reclutamiento
- Fiel Wellness Clinical Research LLC
-
Contacto:
- Osvaldo Caroma, MD
-
Miami, Florida, Estados Unidos, 33155
- Reclutamiento
- United Clinical Research
-
Contacto:
- Teresa B. Alfonso, MD
-
Contacto:
- Alfonso
-
Miami, Florida, Estados Unidos, 33173
- Reclutamiento
- Atlantis Clinical Research, LLC
-
Contacto:
- Leyvi Alvarado Miranda, MD
-
Miami, Florida, Estados Unidos, 33183
- Reclutamiento
- Farma Medical Inc.
-
Contacto:
- Ingrid Fernandez-Milian, MD
-
Miami, Florida, Estados Unidos, 33173
- Reclutamiento
- Baptist Health Miami Cardiac and Vascular Institute
-
Contacto:
- Jonathan Fialkow, MD
-
Miami, Florida, Estados Unidos, 33186
- Reclutamiento
- New Access Research and Medical Center
-
Contacto:
- Sander Fernandez, MD
-
Miami Beach, Florida, Estados Unidos, 33140
- Reclutamiento
- Quantum Clinical Trials
-
Contacto:
- Christopher A. Fayeghi, MD
-
Pensacola, Florida, Estados Unidos, 32504
- Reclutamiento
- Ascension Sacred Heart
-
Contacto:
- Rohit Amin, MD
-
Pompano Beach, Florida, Estados Unidos, 33060
- Reclutamiento
- Clinical Research Center of Florida
-
Contacto:
- Howard S. Koch, MD
-
Tampa, Florida, Estados Unidos, 33620
- Reclutamiento
- University of South Florida
-
Contacto:
- Shone Almeida, MD
-
-
Georgia
-
Augusta, Georgia, Estados Unidos, 30907
- Reclutamiento
- Aiyan Diabetes Center
-
Contacto:
- Anthony D. Turner, MD
-
Dunwoody, Georgia, Estados Unidos, 30338
- Reclutamiento
- Emory University
-
Contacto:
- Ambar Kulshreshtha, MD
-
Fayetteville, Georgia, Estados Unidos, 30214
- Reclutamiento
- Privia Medical Group Georgia LLC -Fayetteville (Javara)
-
Contacto:
- Charlotte Grayson Mathis, MD
-
Lithia Springs, Georgia, Estados Unidos, 30122
- Reclutamiento
- Randomize Now- Atlanta West
-
Contacto:
- Millard Collier Jr., MD
-
Macon, Georgia, Estados Unidos, 31210
- Reclutamiento
- Randomize Now-Burton Medical
-
Contacto:
- Frederick Burton, MD
-
Norcross, Georgia, Estados Unidos, 30092
- Reclutamiento
- Evergreen Clinical Trials
-
Contacto:
- Dmitriy Pelishev, MD
-
Powder Springs, Georgia, Estados Unidos, 30127
- Reclutamiento
- Peachtree Clinical Solutions - Noir Research Collective
-
Contacto:
- Karan Raghavan, MD
-
Riverdale, Georgia, Estados Unidos, 30296
- Reclutamiento
- Randomize Now, LLC - Noir Research Collective
-
Contacto:
- Claire K. Willie, MD
-
Savannah, Georgia, Estados Unidos, 31406
- Reclutamiento
- Privia Medical Group Georgia, LLC (Javara Inc.)
-
Contacto:
- Thomas G. Moriarity, MD
-
Thomasville, Georgia, Estados Unidos, 31792
- Reclutamiento
- Privia Medical Group Georgia - Thomasville (Javara)
-
Contacto:
- William L. Cooper, MD
-
-
Idaho
-
Meridian, Idaho, Estados Unidos, 83642
- Reclutamiento
- Care Institute- High Desert
-
Contacto:
- David A. Hinchman, MD
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Reclutamiento
- Northwestern University
-
Contacto:
- Paul C. Cremer, MD
-
Glenview, Illinois, Estados Unidos, 60026
- Reclutamiento
- Northshore University Health System
-
Contacto:
- Amit K. Pursnani, MD
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46237
- Reclutamiento
- Franciscan Physician Network- Indiana Heart Physicians
-
Contacto:
- Ryan P Daly, MD
-
Indianapolis, Indiana, Estados Unidos, 46202
- Reclutamiento
- Indiana Medical Research Institute
-
Contacto:
- Arshad P. Malik
-
-
Iowa
-
West Des Moines, Iowa, Estados Unidos, 50266
- Reclutamiento
- MercyOne Iowa Heart Center
-
Contacto:
- Enrico L. Martin, MD
-
-
Kentucky
-
Edgewood, Kentucky, Estados Unidos, 41017
- Reclutamiento
- St Elizabeth Health Care - CRI
-
Contacto:
- Erica Pivato, MD
-
Louisville, Kentucky, Estados Unidos, 40202
- Reclutamiento
- UofL Health
-
Contacto:
- Shahab Ghafghazi, MD
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos, 70127
- Reclutamiento
- Ascension DePaul Services Research Center
-
Contacto:
- Kristen Thomas, MD
-
-
Maryland
-
Bowie, Maryland, Estados Unidos, 20715
- Reclutamiento
- Flourish Bowie dba Flourish Research
-
Contacto:
- Sara Collins, MD
-
Columbia, Maryland, Estados Unidos, 21045
- Reclutamiento
- KUR Research at CMP
-
Contacto:
- William Saway, MD
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Reclutamiento
- Brigham and Women's Hospital
-
Contacto:
- Ron Blankstein, MD
-
Boston, Massachusetts, Estados Unidos, 02114
- Reclutamiento
- Massachusetts General Hospital
-
Contacto:
- Pradeep Natarajan, MD
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48202
- Reclutamiento
- Henry Ford Hospital
-
Contacto:
- Cori E Russell, MD
-
Ypsilanti, Michigan, Estados Unidos, 48917
- Reclutamiento
- Trinity Health Michigan Heart
-
Contacto:
- Ahmad Mizyed, MD
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55407
- Reclutamiento
- Minneapolis Heart Institute Foundation
-
Contacto:
- Michael D. Miedema, MD
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Reclutamiento
- Washington University School of Medicine
-
Contacto:
- Farhan M. Katchi, MD
-
St Louis, Missouri, Estados Unidos, 63136
- Reclutamiento
- Saint Louis Heart and Vascular
-
Contacto:
- Gil Vardi, MD
-
-
Montana
-
Kalispell, Montana, Estados Unidos, 59901
- Reclutamiento
- Boeson Research Kalispell
-
Contacto:
- Justin Buls, MD
-
Missoula, Montana, Estados Unidos, 59804
- Reclutamiento
- Boeson Research Fort Missoula
-
Contacto:
- Audrey Remmers, MD
-
-
Nebraska
-
Lincoln, Nebraska, Estados Unidos, 68506
- Reclutamiento
- Bryan Heart
-
Contacto:
- Chad E. Travers, MD
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89128
- Reclutamiento
- Vector Clinical Trials
-
Contacto:
- Bharat R. Mocherla, MD
-
Las Vegas, Nevada, Estados Unidos, 89102
- Reclutamiento
- Southwest Medical Associates- Optum Nevada
-
Contacto:
- Tatiana O. Tsvetkova, MD
-
-
New Jersey
-
Flemington, New Jersey, Estados Unidos, 08822
- Reclutamiento
- Advanced Heart and Vascular Institute of Hunterdon
-
Contacto:
- Andrey Espinoza, MD
-
Marlton, New Jersey, Estados Unidos, 08053
- Reclutamiento
- Virtua Health, Inc.
-
Contacto:
- Mark T. Finch, MD
-
New Brunswick, New Jersey, Estados Unidos, 08901
- Reclutamiento
- Rutgers State University
-
Contacto:
- Sabahat Bokhari, MD
-
Paramus, New Jersey, Estados Unidos, 07652
- Reclutamiento
- The Valley Hospital
-
Contacto:
- Himanshu Gupta, MD
-
Teaneck, New Jersey, Estados Unidos, 07666
- Reclutamiento
- Holy Name Medical Center
-
Contacto:
- Jaffar Raza, MD
-
-
New York
-
Brooklyn, New York, Estados Unidos, 11221
- Reclutamiento
- Clindove Research
-
Contacto:
- Nelly Cohen, MD
-
Brooklyn, New York, Estados Unidos, 11226
- Reclutamiento
- Swift Clinical Research
-
Contacto:
- Manoj Dalmia, MD
-
Jackson Heights, New York, Estados Unidos, 11372
- Reclutamiento
- Rasaj Research
-
Contacto:
- Ammara Mushtaq, MD
-
Lake Success, New York, Estados Unidos, 11042
- Reclutamiento
- Optum- Long Island NY
-
Contacto:
- Steven Goldberg, MD
-
Mount Kisco, New York, Estados Unidos, 10549
- Reclutamiento
- Northwell Health Northern Westchester Hospital
-
Contacto:
- Margaret Andersen, MD
-
New York, New York, Estados Unidos, 10019
- Reclutamiento
- Mount Sinai West
-
Contacto:
- Waqas A Malick, MD
-
New York, New York, Estados Unidos, 10029
- Reclutamiento
- Mount Sinai
-
Contacto:
- Solomon Bienstock, MD
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27599
- Reclutamiento
- University of North Carolina at Chapel Hill
-
Contacto:
- Matthew Cavender, MD
-
Durham, North Carolina, Estados Unidos, 27701
- Reclutamiento
- Duke University Hospital
-
Contacto:
- William Yancy, MD
-
Durham, North Carolina, Estados Unidos, 27705
- Reclutamiento
- Durham Veterans Affairs Medical Center (Durham VAMC)
-
Contacto:
- Hayden Bosworth, MD
-
Fayetteville, North Carolina, Estados Unidos, 28304
- Reclutamiento
- Cape Fear Valley Health System (Javara Inc.)
-
Contacto:
- Nafisa Saleem, MD
-
Morehead City, North Carolina, Estados Unidos, 28557
- Activo, no reclutando
- West Clinical Research
-
Winston-Salem, North Carolina, Estados Unidos, 27157
- Reclutamiento
- Wake Forest University Health Sciences
-
Contacto:
- Michael Shapiro, MD
-
-
North Dakota
-
Fargo, North Dakota, Estados Unidos, 58102
- Reclutamiento
- Sanford Health
-
Contacto:
- David J. Clardy, MD
-
-
Ohio
-
Akron, Ohio, Estados Unidos, 44304
- Reclutamiento
- Summa Health
-
Contacto:
- Wissam Alajaji, MD
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73109
- Reclutamiento
- Medical Research International, LLC
-
Contacto:
- Joseph Grillo, MD
-
Oklahoma City, Oklahoma, Estados Unidos, 73007
- Reclutamiento
- Hightower Clinical
-
Contacto:
- Faisal Latif, MD
-
Tulsa, Oklahoma, Estados Unidos, 74104
- Reclutamiento
- Ascension St. John - Jane Phillips Medical Center
-
Contacto:
- Michael Megaly, MD
-
-
Pennsylvania
-
Camp Hill, Pennsylvania, Estados Unidos, 17011
- Reclutamiento
- Capital Area Research
-
Contacto:
- Venkatesh Nadar, MD
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29425
- Reclutamiento
- Medical University of South Carolina
-
Contacto:
- Marc-Andre Cornier, MD
-
-
Tennessee
-
Cleveland, Tennessee, Estados Unidos, 37312
- Reclutamiento
- Community DPC
-
Contacto:
- Carlton Volberg, MD
-
Knoxville, Tennessee, Estados Unidos, 37920
- Reclutamiento
- University of Tennessee Medical Center
-
Contacto:
- Kashif A. Shaikh, MD
-
Nashville, Tennessee, Estados Unidos, 37202
- Reclutamiento
- TriStar Centennial Medical Center (HCA Health Care)
-
Contacto:
- David Huneycutt, MD
-
-
Texas
-
Abilene, Texas, Estados Unidos, 79601
- Reclutamiento
- Hendrick Health
-
Contacto:
- Ren Zhang, MD
-
Beaumont, Texas, Estados Unidos, 77702
- Reclutamiento
- Gadolin Research
-
Contacto:
- John T Fowler, MD
-
Greenville, Texas, Estados Unidos, 75402
- Reclutamiento
- CardioVoyage, LLC
-
Contacto:
- Marc Demyun, MD
-
Houston, Texas, Estados Unidos, 77025
- Reclutamiento
- Kelsey Research Foundation
-
Contacto:
- Rohan R Wagle, MD
-
Houston, Texas, Estados Unidos, 77004
- Reclutamiento
- Helium Research Group
-
Contacto:
- Ijeoma A. Ekeruo
-
Houston, Texas, Estados Unidos, 77070
- Reclutamiento
- Gulf Coast Clinical Research, LLC
-
Contacto:
- Anjani Pandya, MD
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- The Methodist Hospital, DeBakey Cardiology Associates
-
Contacto:
- Sadeer Al-Kindi, MD
-
Laredo, Texas, Estados Unidos, 78041
- Reclutamiento
- Aeres Clinical Research
-
Contacto:
- Amando Garza, MD
-
Lewisville, Texas, Estados Unidos, 75057
- Reclutamiento
- DC Clinical Research
-
Contacto:
- Moiz M. Shafiq, MD
-
McKinney, Texas, Estados Unidos, 75069
- Reclutamiento
- North Dallas Research Associates - Kerlo Network
-
Contacto:
- Muhammad Akram Khan, MD
-
Mesquite, Texas, Estados Unidos, 75149
- Reclutamiento
- SMS Clinical Research
-
Contacto:
- Salma Saiger, MD
-
San Marcos, Texas, Estados Unidos, 78666
- Reclutamiento
- Privia Medical Group Gulf Coast, PLLC ( Javara Inc.)
-
Contacto:
- Alan Lee, MD
-
Stephenville, Texas, Estados Unidos, 76401
- Reclutamiento
- Privia Medical Group- North Texas
-
Contacto:
- Benjamin Marcum, MD
-
-
Utah
-
West Valley City, Utah, Estados Unidos, 84120
- Aún no reclutando
- Kalo Clinical Research
-
Contacto:
- William J. Walsh, MD
-
-
Virginia
-
Richmond, Virginia, Estados Unidos, 23225
- Reclutamiento
- Chippenham Johnston Willis Medical Center
-
Contacto:
- Michael Arcarese, MD
-
-
Washington
-
Everett, Washington, Estados Unidos, 98201
- Reclutamiento
- Providence Regional Medical Center Everett
-
Contacto:
- Xiaojing Jennie Shen, MD
-
Seattle, Washington, Estados Unidos, 98195
- Reclutamiento
- University of Washington
-
Contacto:
- Kelley Branch, MD
-
-
West Virginia
-
Charleston, West Virginia, Estados Unidos, 25304
- Reclutamiento
- Charleston Area Medical Center
-
Contacto:
- Sarah Rinehart, MD
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Provided electronic or written informed consent
-
Men > 55, women > 65 years of age
-
Type 2 diabetes mellitus requiring pharmacologic therapy or with their most recent A1c 6.5%. Patients with prediabetes (most recent HbA1c 5.7 to 6.4% and/or fasting glucose 100-125 mg/dL [5.6-6.9 mmol/L]) and/or metabolic syndrome can be enrolled through 12 October 2026 and proceed with randomization; however, no additional participants may enroll with these criteria after this date. Metabolic syndrome is defined as > 3 of the following criteria (International Diabetes Federation 2006):
- Body mass index ≥ 27 kg/m2 or abnormal waist circumference defined as ≥ 80 cm (31.5 inches) for women, ≥ 94 cm (37 inches) for men; for South and East Asian men (e.g., Asian Indian, Chinese, Japanese) ≥ 90 cm (35.4 inches)
- Fasting triglycerides ≥ 150 mg/dL (1.7 mmol/L) or treated hypertriglyceridemia
- HDL-cholesterol (HDL-C) < 40 mg/dL (1.03 mmol/L) in men, <50 mg/dL (1.29 mmol/L) in women or treatment for this lipid abnormality
- Systolic blood pressure (BP) ≥ 130 and/or diastolic BP≥ 85 mm Hg and/or treated hypertension
- Fasting blood glucose ≥ 100 mg/dL (5.6 mmol/L) or HbA1c ≥ 5.7%
-
Have a device (e.g., smartphone, tablet, computer) for communication with the central cardiologist-led team managing drug treatment for the personalized care group
Exclusion Criteria:
-
Any one of the following:
- A history of acute myocardial infarction (heart attack), stroke, or non-traumatic leg/foot/toe amputation
- A history of an arterial revascularization procedure for coronary, peripheral, and/or carotid atherosclerotic disease (i.e. coronary stent or bypass, carotid stent)
- Symptoms suspicious of coronary artery disease, stroke or peripheral artery disease confirmed by a diagnostic test within the last 12 months (i.e. nuclear stress test, invasive angiogram, brain MRI/CT
- Asymptomatic ASCVD including treatment with therapies (e.g. antiplatelets, lipid lowering) intended to reduce CV risk due to the imaging evidence of atherosclerosis and/or management to goals consistent with secondary prevention guidelines (e.g. LDL-C < 70 mg/dL)
-
Planned arterial revascularization
-
Inability to complete screening CCTA or any condition that would increase the risk associated with CCTA or increase likelihood of uninterpretable scan including:
- eGFR < 60 mL/min/1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) or Modification of Diet in Renal Disease (MDRD) equation (www.kidney.org/professionals/kdoqi/gfr_calculator)
- Allergy to iodinated contrast or history of contrast-induced nephropathy (including adverse reaction to contrast at screening CCTA) or screening laboratory values consistent with untreated hyperthyroidism. Participants with elevated thyroid-stimulating hormone (TSH) may be enrolled but should be referred to their physician for evaluation for treatment.
- Thyroid cancer in the previous five (5) years or planned radioactive iodine treatment
- Weight > 300 lbs. (136 kg) or above manufacturer-recommended limit for scanner and table at the site
- Inability to hold breath for > 10 seconds
- Active arrhythmia (atrial fibrillation, atrial flutter, frequent premature atrial, or ventricular contractions) with poorly controlled rate (i.e., > 80 beats per minute at screening or prior to CCTA)
- Contraindication to dosing with beta blocker or nitroglycerin on day of screening CCTA
- Any other factor that, in the opinion of the investigator, would increase participant risk or increase the chance of an uninterpretable CCTA
-
Unsuitable as a trial participant in the opinion of the investigator for reasons including significant left main stenosis (e.g. ≥ 70%; site will be notified by Cleerly), other health condition with life expectancy < 3 years or being at risk of poor compliance with study procedures (e.g., active substance abuse or untreated mental illness that, in the opinion of the investigator, is likely to adversely affect adherence or retention)
-
Unwilling or unable to receive specialty care per the trial protocol
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Sin intervención: Risk Factor-Based Care
The risk factor-based care group will be managed by their usual care providers, with an initial pre-randomization assessment of current treatment by a centralized cardiology team to optimize care relative to primary prevention guidelines. During the trial, the centralized cardiology team will monitor the provision of medications prescribed and lab values relative to guidelines, and provide feedback and education to site investigators to support optimization. CCTA results will be centrally archived and will remain blinded to the usual care provider until the end of the study. |
|
|
Experimental: Cleerly Stage-Based Care
The Cleerly Stage-Based Care group will receive personalized care centrally managed by a remote cardiologist-led team. They will also receive an initial pre-randomization assessment of current treatment by a centralized cardiology team to optimize care relative to primary prevention guidelines. Cleerly CAD Staging System results will be discussed with participants and serve as the basis for standardized algorithm-supported pharmacotherapy & education, which will be intensified if plaque burden has progressed at 24 months. |
The Cleerly CAD Staging System is software that utilizes a proprietary algorithm to identify CAD, stage the severity of CAD when present, and generate a prognostic risk score to inform treatment decisions that support CV disease prevention. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
The primary objective is to compare Cleerly stage-based care with risk factor-based care on the risk of CV events.
Periodo de tiempo: Through study completion- an average of 3.5 years
|
The primary endpoint is total (first and subsequent) events for the composite endpoint of CV death, myocardial infarction (MI), ischemic stroke, acute limb ischemia, clinically driven arterial revascularization, and hospitalization or urgent visit for heart failure. |
Through study completion- an average of 3.5 years
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
The secondary objective is to compare Cleerly CAD stage-based care with risk factor-based care on other clinical events of CV and renal morbidity and mortality.
Periodo de tiempo: Through study completion- an average of 3.5 years
|
The secondary endpoints are time from randomization to first occurence of an event in the primary efficacy endpoint. |
Through study completion- an average of 3.5 years
|
|
The secondary objective is to compare Cleerly CAD stage-based care with risk factor-based care on other clinical events of CV and renal morbidity and mortality.
Periodo de tiempo: Through study completion- an average of 3.5 years
|
The secondary endpoints are total occurences after randomization of the primary efficacy endpoing, kidney failure, sustained estimated glomerular filtration rate (eGFR) decrease >40% from baseline, and death from renal causes. |
Through study completion- an average of 3.5 years
|
|
The secondary objective is to compare Cleerly CAD stage-based care with risk factor-based care on other clinical events of CV and renal morbidity and mortality.
Periodo de tiempo: Through study completion- an average of 3.5 years
|
The secondary endpoints are first and total occurrences after randomization of coronary death, MI, and urgent coronary revascularization. |
Through study completion- an average of 3.5 years
|
|
The secondary objective is to compare Cleerly CAD stage-based care with risk factor-based care on other clinical events of CV and renal morbidity and mortality.
Periodo de tiempo: Through study completion- an average of 3.5 years
|
The secondary endpoints are time from randomization to first occurrence of MI or ischemic stroke. |
Through study completion- an average of 3.5 years
|
|
The secondary objective is to compare Cleerly CAD stage-based care with risk factor-based care on other clinical events of CV and renal morbidity and mortality.
Periodo de tiempo: Through study completion- an average of 3.5 years
|
The secondary endpoints are time from randomization to all-cause death. |
Through study completion- an average of 3.5 years
|
Otras medidas de resultado
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
The safety objective is to assess harm with the 2 prevention strategies
Periodo de tiempo: Through study completion- an average of 3.5 years
|
The safety endpoints are Adverse events (AE) leading to discontinuation of study-recommended medication (DAE), serious AE (SAE), adverse device effect (ADE). |
Through study completion- an average of 3.5 years
|
|
The safety objective is to assess harm with the 2 prevention strategies
Periodo de tiempo: Through study completion- an average of 3.5 years
|
The safety endpoints are 20-item Short Form survey (SF-20). |
Through study completion- an average of 3.5 years
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Silla de estudio: Deepak Bhatt, MD, MPH, Mt. Sinai Heart
- Silla de estudio: David J. Maron, MD, FASPC, Stanford University
Publicaciones y enlaces útiles
Publicaciones Generales
- Clerc OF, Fuchs TA, Stehli J, Benz DC, Grani C, Messerli M, Giannopoulos AA, Buechel RR, Luscher TF, Pazhenkottil AP, Kaufmann PA, Gaemperli O. Non-invasive screening for coronary artery disease in asymptomatic diabetic patients: a systematic review and meta-analysis of randomised controlled trials. Eur Heart J Cardiovasc Imaging. 2018 Aug 1;19(8):838-846. doi: 10.1093/ehjci/jey014.
- Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, Boehme AK, Buxton AE, Carson AP, Commodore-Mensah Y, Elkind MSV, Evenson KR, Eze-Nliam C, Ferguson JF, Generoso G, Ho JE, Kalani R, Khan SS, Kissela BM, Knutson KL, Levine DA, Lewis TT, Liu J, Loop MS, Ma J, Mussolino ME, Navaneethan SD, Perak AM, Poudel R, Rezk-Hanna M, Roth GA, Schroeder EB, Shah SH, Thacker EL, VanWagner LB, Virani SS, Voecks JH, Wang NY, Yaffe K, Martin SS. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022 Feb 22;145(8):e153-e639. doi: 10.1161/CIR.0000000000001052. Epub 2022 Jan 26.
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- 202302CPC
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .